Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
The aim is to create new genomics solutions that could combat cancer and advance market access
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
The approval is supported by results from the Phase 3 SWOG 1826 trial
Subscribe To Our Newsletter & Stay Updated
